Holigen Global Health
Holigen Premium European Cultivator
Akanda owns a one-of-a-kind CB operation in Portugal - Holigen.
Holigen consists of a high-quality 20,000 square foot indoor facility located near Lisbon (in Sintra) dedicated to the cultivation of high-T-H-C premium CB, one of a limited number of fully certified EU GMP of its kind in Europe, as well as a large seven million square foot (180+ acres) outdoor facility located two hours south in Aljustrel.
Combined, these facilities provide the flexibility of capacity in Portugal to produce two tonnes of 1P premium indoor CB, over 100 tonnes of 1P outdoor CB, and over eight tonnes of 3P manufacturing capacity annually.
Cansativa Group
European Distribution - Cansativa European Distributor
Akanda Corp. and Cansativa GmbH have a new cooperation that will allow German pharmacies to provide patients with two novel CB cultivars.
This collaboration allows the Cansativa platform to supply the German market with dried flowers from Akanda's EU-GMP certified indoor grow facility in Sintra, Portugal.
Akanda is expected to deliver at least 1,000 kilograms to Cansativa over the first 12-month term of the agreement.
CanMart
UK Based Distribution - CanMart UK Distributor
Akanda's wholly owned subsidiary CanMart Ltd. is one of a limited number of fully licensed UK importers and wholesalers of medical CB to patients in the UK.
CanMart provides route to market for CB grown at Bophelo's campus in Lesotho as well as an independent "open marketplace" supply chain solution into the UK for registered global CB companies looking to enter the European market.
Cellen
UK Patient Access - Cellen/Leva UK Clinic
Akanda is partnered with UK digital healthcare leader Cellen and its fully integrated pain service to provide access to CB based medication for patients in need.
Cellen's Leva Clinic (CQC registered) is the first fully online clinic for patients with chronic pain partnered with the NHS and Boots.
Leva's multidisciplinary clinical team comprises expert clinicians, clinical psychologists, physiotherapists and nurse consultants.
The team supports patients through personalized online care plans.
Grab More Key Details Here: Akanda's Wesbite.
-----
As mentioned above, AKAN has several key potential catalysts to keep a close eye on. Check them out:
No. 1 AKAN Potential Catalyst - A Crazy Low Float Could Lead To Explosive Volatility!
According to info pulled from Yahoo Finance's website, AKAN has a minuscule float.
The website reports this profile to have roughly 760.62Mn shares in its float.
Why is that figure important? It's important on one crucial level. Volatility.
Could more positive company news in mid-2024 provide a near term spark?
-----
No. 2 AKAN Potential Catalyst - A First-Mover Attitude Could Propel AKAN To International Recognition.
Akanda Corp. Announces Plans to Be Among International First Movers Pending Completion of Landmark Change in US Drug Policy
London, United Kingdom--(Newsfile Corp. - May 10, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company")..., today announces it is actively following the landmark change in federal US policy to reschedule CB under the Controlled Substances Act ("CSA"). It has been widely reported that as of April 30, 2024 the DEA plans to reclassify CB as a Schedule III substance. The Company believes this imminent rescheduling may reinvigorate capital markets and could lead to changes in NASDAQ and NYSE rules on listing plant-touching U.S. companies. Should this occur and provided NASDAQ rule changes, Akanda has strategic plans to become a leader in consolidating US-based operators.
...
Ms. Field commented, "Akanda's Board and Management have subject matter expertise in multiple global markets including the United States. We are closely monitoring the loosening of federal regulations and plan to explore US opp's. Some US markets are more depressed than others offering a unique opp. to capitalize on low entry prices of licenses or licensed operations."
Read the full article here.
-----
No. 3 AKAN Potential Catalyst - The Addition Of Block-chain And AI Solutions Could Separate AKAN From The Competition.
Akanda Announces Plans to Enter Block-chain and AI Technology Sector
London, United Kingdom--(Newsfile Corp. - April 12, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), ..., announces its plans to enter the block-chain and artificial intelligence sector of the CB industry.
With an increasingly complex and global supply chain for the international CB industry, the Company believes companies and consumers will turn to block-chain and smart contracts to verify the authenticity of genetics, plants, and products alike. There are numerous advantageous applications of this technology such as harnessing block-chain capabilities to certify all clones, or baby plants, with a batch certificate. CB nurseries specialize in plant genetics, producing clones and baby plants and seeds for the purpose of wholesale distribution.
Interim CEO and Director Katie Field commented, "Everyone from consumers, to growers, to manufacturers, to retailers care very much about the stages of production from seed to sale. We believe this technology can be used to verify the authenticity clones and genetic lineage."
The Company believes other applications of block-chain include "track and trace" software for inventory and lab testing results. By utilizing this technology Certificate of Analyses (COAs) will be available at the end customer's fingertips to trace results back to the original laboratory. Block-chain technology provides traceability.
Akanda believes Block-chain solutions will complement the artificial intelligence capability being developed at Canmart. Presently Canmart plans to partner with a platform developed by its directors to make medical CB more accessible to UK patients both with social shopping trends and tailored products. Access Kaneh utilizes an AI algorithm that analyzes DNA vis a vis products in the UK market. EndoDNA is a breakthrough test that matches patients with solutions for an individualized wellness journey.
...
Ms. Field commented, "Akanda is competing in the brave new world of global CB and we intend to stay at the forefront of it by evaluating the technological solutions that can be leveraged in the business and scaled for our customers and end users. We are excited at the prospect to adopt cutting-edge technology that is a game-changer for companies and consumers alike."
...
Read the full article here.
-----
No. 4 AKAN Potential Catalyst - Germany Becomes 3rd European Union Country To Take The Major LGLization Leap (AKAN Anticipates Strong Acquisition Potential!)
Akanda Looks to Commercialize and Capitalize on Germany's LGLization of CB, Opening Path to $3Bn Market
London, United Kingdom--(Newsfile Corp. - April 12, 2024) - Akanda Corp. (NASDAQ: AKAN) ("Akanda" or the "Company"), ..., Akanda Corp. announces its plans to evaluate and pursue strategic in-vest-ments in the expanded LGLized German market.
On April 1, 2024, Germany became the third European Union country to LGLize CB for personal use after Malta and Luxembourg. The new law LGLizes recreational possession, individuals to grow up to three plants, and joining CB clubs to buy up to 25 grams per day.
As a result of the expanded CB LGLization, Akanda anticipates exciting potential growth opp's in the German market and is reviewing potential acquisitions and strategic in-vest-ments in the region. The Company is optimistic about these prospects and will look to focus on a pathway for commercialization in the German market. The sectors of particular interest to the Company are cultivation, production, retail and dispensaries; where the team management and board have significant experience.
Akanda believes the expansion both in medical and allowing for recreational use may increase German patient and consumer demand and likewise German regulators will create an infrastructure of imports and licensed manufacturing to accommodate its growing market. Akanda plans to closely monitor regulatory developments and the licensing process as well as evaluate current licensed operating targets for acquisition. The Company also anticipates the landmark reforms in Germany could have an impact on CB drug policy across Europe as other countries may adopt Germany's approach.
"We applaud Germany's increased access to valid medicine and products for patients and consumers. This legislation represents a critical step and illustrates a public policy model for other European Union countries," stated Katie Field interim CEO and Director. Ms. Field continued, "Akanda is evaluating opp's to participate in the leading edge of this market and aspires to provide German consumers with exceptional CB products."
...
Read the full article here.
-----
No. 5 AKAN Potential Catalyst - Could Oversold Leaning Technicals Suggest A Healthy Reversal Is Nearing?
Here's what was cooking at noon EST on Thursday. Barchart was reporting multiple oversold technical indicators for AKAN.
These technicals could be signaling a healthy reversal to be approaching in the near term.
Here's the definition of a "reversal" from Investopedia:
"A reversal is a change in the price direction of an asset. A reversal can occur to the upside or downside. Following an uptrend, a reversal would be to the downside. Following a downtrend, a reversal would be to the upside. Reversals are based on overall price direction and are not typically based on one or two periods/bars on a chart."
Here are the technicals to pay close attention to (as of 12:00PM EST Thursday):
- 9-Day Relative Strength Index: 20.82%
- 14-Day Relative Strength Index: 28.40%
When these numbers drop down to the 30% range and lower, they can be viewed as being in oversold territory. While in this territory, they can paint the picture of a profile that is undervalued.
- 14-Day Raw Stochastic: 9.62%
- 14-Day Williams %R: 90.38%
As the Raw Stochastic nears the 10% range and lower and the Williams %R nears the 90% range or higher, these technical indicators may also be viewed as oversold and undervalued.
Keep an eye on these technicals closely.
-----
(Nasdaq: AKAN) Recap - 5 Potential Breakout Catalysts To Know Right Now!
No. 1 - A Crazy Low Float Could Lead To Explosive Volatility!
No. 2 - A First-Mover Attitude Could Propel AKAN To International Recognition.
No. 3 - The Addition Of Block-chain And AI Solutions Could Separate AKAN From The Competition.
No. 4 - Germany Becomes 3rd European Union Country To Take The Major LGLization Leap (AKAN Anticipates Strong Acquisition Potential!)
No. 5 - Could Oversold Leaning Technicals Suggest A Healthy Reversal Is Nearing?
-----
Coverage is officially initiated on (Nasdaq: AKAN). I'll be in touch with updates when necessary.
For now, get this Nasdaq breakout idea on your screen. Talk again soon.
Sincerely,
Kai Parker
StockWireNews
Source 1
Source 2
(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)
Post a Comment
Post a Comment